

SIMPOSIO DE ESPECTROMETRÍA DE
MASAS, RESONANCIA MAGNÉTICA,
SECUENCIACIÓN DEL GENOMA:
**Nuevos caminos para la industria y las
universidades del siglo XXI**

8 y 9 de septiembre de 2017

Rudolf Grimm

Rudi Grimm received his Ph.D. in Biology from the Ludwig-Maximilians University of Munich/Germany. After completing a post-doc time at the University of Freiburg/Germany and the Riken Institute in Tokyo/Japan he joined Hewlett-Packard as a senior life science application chemist in 1991. In 1998, he became the head of protein chemistry at the Munich based proteomics start-up company Toplab. In June 1999, he joined Hexal Pharma (now part of Sandoz/Novartis) to establish the Biotech Laboratories for the successful development of biosimilar drugs such as EPO.



In September 2002, he joined Agilent Technologies as the worldwide proteomics and metabolomics market development manager. From January 2009 until May 2015 he was a Director of Science and Technology at Agilent Technologies managing worldwide key strategic academic collaborations. In September 2010 Rudi became an Adjunct Professor at the University of California in Davis and in August 2011 an Adjunct Professor at Chungnam National University in Daejeon/South-Korea. End of June 2017 he re-joined Agilent Technologies as their global university research program manager. He is currently author and co-author of 134 scientific publications. His main interest is in paleo-multiomics research.